During the past decade, Institute for pulmonary diseases of Vojvodina conducted 26 clinical trials. In the 10-year time frame, 26 clinical trials started and 12 clinical trials were completed, i.e. on average, 46.2% percent of trials that started reached the finish line to date. In the past 5 years, 14 clinical trials started and 8 clinical trials were completed. i.e. 57.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Institute for pulmonary diseases of Vojvodina" #1 sponsor was "Hoffmann-La Roche" with 12 trials, followed by "Incyte Corporation" with 2 trials sponsored, "Aileron Therapeutics, Inc." with 1 trials sponsored, "Altavant Sciences GmbH" with 1 trials sponsored and "Arcus Biosciences, Inc." with 1 trials sponsored. Other sponsors include 9 different institutions and companies that sponsored additional 19 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Institute for pulmonary diseases of Vojvodina" #1 collaborator was "Cephalon" with 1 trials as a collaborator, "Gilead Sciences" with 1 trials as a collaborator, "Institute for Pulmonary Diseases of Vojvodina" with 1 trials as a collaborator, "Merck KGaA, Darmstadt, Germany" with 1 trials as a collaborator and "Universiteit Antwerpen" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 7 trials.

According to Clinical.Site data, the most researched conditions in "Institute for pulmonary diseases of Vojvodina" are "Non-Small Cell Lung Cancer" (6 trials), "Lung Cancer" (2 trials), "NSCLC" (2 trials), "Non Small Cell Lung Cancer" (2 trials) and "Non-Squamous Non-Small Cell Lung Cancer" (2 trials). Many other conditions were trialed in "Institute for pulmonary diseases of Vojvodina" in a lesser frequency.

Most popular intervention types in "Institute for pulmonary diseases of Vojvodina" are "Drug" (30 trials), "Device" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Carboplatin" (10 trials), "Placebo" (9 trials), "Atezolizumab" (6 trials), "Cisplatin" (6 trials) and "Pemetrexed" (6 trials). Other intervention names were less common.

The vast majority of trials in "Institute for pulmonary diseases of Vojvodina" are 31 trials for "All" genders.

Currently, there are NaN active trials in "Institute for pulmonary diseases of Vojvodina". undefined are not yet recruiting, 8 are recruiting, 8 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 11 completed trials in Institute for pulmonary diseases of Vojvodina, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Institute for pulmonary diseases of Vojvodina, 2 "Phase 1" clinical trials were conducted, 8 "Phase 2" clinical trials and 18 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 0 trials that are defined as “Not Applicable".

Institute for pulmonary diseases of Vojvodina has several departments that took part in Clinical trials: "Institute for Pulmonary Disease of Vojvodina" - 5 trials, "Inst. for Pulm. Diseases of Vojvodine, Clinic f. Pulm. Oncol" - 3 trials